Clinical trials: Early Parkinson's Disease
Parkinson Disease
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist.
- Trial name
- PARADYSE (NCT01155479)
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 1,022 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
Comparison of the Incidence of Dyskinesia in Parkinson's Disease Who Were Treated With Amantadine or Dopamine Agonist
The purpose of this study is to compare the onset time and severity of dyskinesia in amantadine or Dopamine agonist initial treated groups in Parkinson's disease.
- Trial name
- NCT01338662
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Hospital
Parkinson's Disease
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
- Trial name
- NCT02337751
- Testing
- TVP-1012 1mg
- Where
- 56 sites in Japan
- Volunteers
- 198 people
- Sponsor
- Takeda
Parkinson's Disease (PD)
A Phase 2 Study to Assess the Effects of SUL-238 on High Energy Phosphates With ³¹P-MRS in Patients With Early, Untreated Parkinson's Disease
The main goal of the study is to investigate how well the new drug SUL-238 works in Parkinson's Disease (PD). This is done by means of an MRS scan. An MRS scan is similar to a regular MRI scan.
- Trial name
- SHEPHERD (NCT07322887)
- Testing
- SUL-238 (1500 mg t.i.d.) film-coated tablets, SUL-238 (500 mg t.i.d.) film-coated tablets
- Where
- Netherlands
- Volunteers
- 45 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Parkinson Disease
Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™
Directly examine whether early (6-month) imaging with DaTscan and [¹⁸F] AV-133 will provide an early signal of disease progression in recently diagnosed untreated PD patients.
- Trial name
- NCT04507139
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Michael J. Fox Foundation for Parkinson's Research
Parkinson's Disease
Measures of Motor Impairment in Early Parkinson's Disease
This study will test the accuracy of a new home-use electronic device that measures and records small changes in Parkinson's disease symptoms, such as tremor and impaired movement and speech.
- Trial name
- NCT00291265
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Early Stage Parkinson's Disease
SLV308 for Treatment of Patients With Early Parkinson's Disease
This study is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 administered as a monotherapy in patients with early stage PD.
- Trial name
- NCT00269516
- Testing
- pardoprunox
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson Disease, Movement Disorders
Characterizing Biomarkers of Early Parkinson's Disease Progression (TREG)
The purpose of this study is to look at a blood marker of inflammation in early untreated Parkinson's disease.
- Trial name
- TREG (NCT03716258)
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Oregon Health and Science University
Parkinson Disease
A Study to Analyze Symptoms Prevalent in Early PD (Dysphonia, Tremor)
This is a web-based study that involves monitoring hallmark symptoms of Parkinson's Disease (PD), specifically dysphonia and tremor, using smartphone sensor data.
- Trial name
- NCT04288804
- Testing
- Smartphone microphone sensor, Smartphone accelerometer sensor
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Goalspal LLC
Parkinson Disease
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
This study is to evaluate the safety and tolerability and to characterize the pharmacokinetics of multiple ascending dose (MAD) of LY03003 following intramuscular injections.
- Trial name
- NCT04045678
- Testing
- LY03003 ( Rotigotine, extended-release microspheres)
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Luye Pharma Group Ltd.
Parkinson Disease
Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease
Multicenter, open-label dose-escalation study
- Trial name
- NCT03204929
- Testing
- Cu(II)ATSM
- Where
- 2 sites in Australia
- Volunteers
- 31 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Early Stage Parkinson Disease
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
This is a multicenter, randomized, double blind, parallel group study of 6 months' treatment with SLV308 as monotherapy in patients with early stage PD.
- Trial name
- NCT00335166
- Testing
- Pardaprunox, pramipexole
- Where
- 89 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson Disease
Diagnostic Tools for Parkinson's Disease
The study aims to identify genetic variants associated to Parkinson's disease through the analysis of exome-sequencing data of familial cases and controls.
- Trial name
- NCT02403765
- Where
- Italy
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Parkinson Disease
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.
The primary purpose of this study is to determine whether sumanirole is effective and safe in the treatment of the signs and symptoms of early Parkinson's disease.
- Trial name
- NCT00036218
- Testing
- sumanirole, ropinirole
- Where
- 102 sites in United States, Argentina and 2 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Parkinson Disease
A Study to Determine the Dose of WIN-1001X by Evaluating Efficacy and Safety in Early Parkinson's Disease Patients
The purpose of this study is to determine the optimal dose of WIN-1001X for its therapeutic confirmatory study by comparing and evaluating the efficacy and safety of each dose group by conducting a therapeutic exploratory study…
- Trial name
- NCT04220762
- Testing
- WIN-1001X
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- Medi Help Line
Parkinson's Disease
The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)
To determine the long-term consequences (8 years) of initiating patients with Parkinson's disease on either pramipexole or levodopa.
- Trial name
- CALM-PD Cohort (NCT00804479)
- Testing
- No intervention.
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- University of Rochester
Parkinson Disease, Neurologic Disorder
Effect of taVNS of Brainstem Activation in Early and Late Parkinson's Disease Patients - an fMRI Study
This is a randomised, within-subject, double-blinded, placebo-controlled study to assess the fMRI correlates of central nervous system (CNS) response to taVNS in early vs late-stage Parkinsons disease (PD), at two different…
- Trial name
- NCT05967598
- Testing
- Noninvasive transcutaneous auricular vagus nerve stimulation at 100Hz, Noninvasive transcutaneous auricular vagus nerve stimulation at 25Hz
- Where
- Slovenia
- Volunteers
- 40 people
- Sponsor
- University of Ljubljana
Parkinson's Disease
Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications.
- Trial name
- NCT00282152
- Testing
- B-STN DBS, Optimal drug therapy
- Volunteers
- 37 people
- Sponsor
- Vanderbilt University Medical Center
Parkinsons Disease (PD)
A Study of NE3107 in Early Parkinson's
The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for…
- Trial name
- SUNRISE-PD (NCT06757010)
- Testing
- NE3107
- Where
- 4 sites in United States
- Volunteers
- 57 people
- Sponsor
- BioVie Inc.
Early Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
- Trial name
- NCT00335374
- Testing
- Pardoprunox
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 202 people
- Sponsor
- Solvay Pharmaceuticals